Can't take anymore WINNING!

Quote

anonymous

Guest
Merck up 13% for the first quarter
Zoetis up 6%
Elanco....flat

After two years of failing, when will Lilly realize that Elanco leadership can not deliver? How much longer can leadership lay the blame on 'customer buying patterns' and 'competitive pressure'?
 






anonymous said:
Merck up 13% for the first quarter
Zoetis up 6%
Elanco....flat

After two years of failing, when will Lilly realize that Elanco leadership can not deliver? How much longer can leadership lay the blame on 'customer buying patterns' and 'competitive pressure'?
Click to expand...
They can do it for 10 more years. Look at Virbac and Ceva
 






When you have no product supply, your numbers go down. Followed by being "up" wHen you actually can supply product. Surprised the fiasco called Virbackorder still exists.
 












Ractopamine sales have to be WAY down. Aggressive discounting has to impact other package goods. But wait, they have the best sales force and Benchmark will save the day LOL LOL! What a bunch of snowflakes that have no idea how to run a business. And be ready, a monensin is coming.....nowhere to hide losers!!
 












ENOUGH! Lol. How can you have all the "fantastic" people, true outliers, those who can build relationships and maintain business? What about Benchmark being the differentiator that keeps loyalty? And all those lame guys delivering info that the customers most know already? Sorry about taking your bonuses away. Sorry about forcing discussions to reduce head count. Not really.......would not have happened with the old Elanco, today you are more concerned about surrounding yourselves with snowflakes that will do as you say and not cause conflict. And trust me, it's only going to get worse! Congrats to ALL those "Directors"!!
 












Animal Health

In the second quarter of 2017, worldwide animal health revenue totaled $784.8 million, a decrease of 9 percent compared with the second quarter of 2016. Worldwide food animal revenue decreased 14 percent, to $473.0 million, driven by market access pressure and competitive pressure in cattle and swine. Worldwide companion animal revenue increased 1 percent, to $311.8 million, driven by the inclusion of $78.3 million in revenue from the acquisition of Boehringer Ingelheim Vetmedica'sU.S. feline, canine and rabies vaccine portfolio, largely offset by wholesaler buying patterns in the second quarter of 2016 and worldwide competitive pressure. The company expects these pressures to continue, to a lesser extent, for the balance of 2017.

Boy oh boy!!!! Food animal down 14%!!!!! What's gonna happen when another monensin hits the market??? Ba bye losers!!!!
 






  • Merck announced financial results for the second quarter of 2017. Animal Health sales totaled $955 million for the second quarter of 2017, an increase of 6% compared with the second quarter of 2016, including a 1% negative impact from foreign exchange. (company press release)
  • Eli Lilly and Company announced financial results for the second quarter of 2017. Revenue for Elanco Animal Health totaled $785 million, a decrease of 9% compared with the second quarter of 2016. (company press release)
  • Bayer reported financial results for the second quarter of 2017. Sales of Animal Health were EUR 450 million ($513 million), an increase of 6% compared to the comparable prior-year period (+2% currency & portfolio adjusted). (company website)
  • Ceva reported results for the first half of 2017. Consolidated sales were EUR 546 million ($623 million), an increase of 20% versus last year and +6.6% at constant perimeter and exchange rates. (company press release)
  • Vetoquinol reported results for the second quarter of 2017. The Group posted sales of EUR 89.5 million ($102 million), up 4% as reported compared to the same period in 2016 (up 2.6% like-for-like). (Business wire)
 






Top Bottom
Back
Quote